Burning Rock Biotech Ltd is a diagnostics & research business based in the US. Burning Rock Biotech Ltd shares (BNR) are listed on the NASDAQ and all prices are listed in US Dollars. Burning Rock Biotech Ltd employs 1,394 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.66 |
|---|---|
| 52-week range | $1.74 - $29.16 |
| 50-day moving average | $3.32 |
| 200-day moving average | $9.53 |
| Wall St. target price | $13.32 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.27 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.66 from 2022-07-01
| 1 week (2022-06-28) | 9.47% |
|---|---|
| 1 month (2022-06-03) | 13.68% |
| 3 months (2022-04-05) | -74.52% |
| 6 months (2022-01-05) | -71.55% |
| 1 year (2021-07-02) | -90.44% |
|---|---|
| 2 years (2020-07-02) | -90.20% |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Revenue TTM | $536.8 million |
|---|---|
| Gross profit TTM | $364.1 million |
| Return on assets TTM | -23.17% |
| Return on equity TTM | -44.46% |
| Profit margin | -165.19% |
| Book value | $15.83 |
| Market capitalisation | $279.8 million |
TTM: trailing 12 months
We're not expecting Burning Rock Biotech Ltd to pay a dividend over the next 12 months.
Burning Rock Biotech Ltd's shares were split on a 1:3 basis on 31 July 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Burning Rock Biotech Ltd shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Burning Rock Biotech Ltd shares which in turn could have impacted Burning Rock Biotech Ltd's share price.
Over the last 12 months, Burning Rock Biotech Ltd's shares have ranged in value from as little as $1.74 up to $29.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Burning Rock Biotech Ltd's is -0.1847. This would suggest that Burning Rock Biotech Ltd's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Burning Rock Biotech Ltd has bucked the trend.
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.